Aibo Medical is a leader in intraocular lens products, a leader in China's ophthalmic medical device industry, and the only manufacturer in China that has successfully achieved pure independent development of multifocal intraocular lenses.
The stock price rose 2 in 3 months4 times
From March to June 2021, the stock price rose from 164 to 387, an increase of 24 timesIn 2022, the stock price doubled from 129 yuan in March to 248 yuan in November.
2021 Aibo Medical stock price chart).
Revenue increased from 04.4 billion yuan, to 57.9 billion yuan, an increase of 13 times in 6 years. In the first three quarters of this year, revenue increased by 51% year-on-year, continuing to maintain rapid growth.
2016-2020 Aibo Medical operating income).
A boon for cataract and childhood myopia
The founder of the company, Xie Jiangbing, received his bachelor's and master's degrees from the Department of Chemistry of Donghua University and went to the University of California, Davis to study for a doctorate. After graduation, he successively served as a senior scientist of Eye Health and the chief scientist of Abbott Laboratories.
During his stay in the United States, Xie Jiangbing learned about the backward status of cataract surgery technology in China at that time, and countless patients were plagued by illness, so he came up with the idea of returning to China to start a business. In 2010, Xie Jiangbing returned to China to found Aibo Medical, becoming one of the earliest enterprises engaged in the research and development of artificial lenses for human eyes in China.
At that time, the technology of intraocular lenses was monopolized by foreign companies, and the domestic price was very expensive, and most patients could not afford it. Aibo Medical has successfully created a domestic aspheric artificial lens, which is affordable for every cataract patient.
Since its launch, the company's intraocular lens products have covered nearly 3,000 hospitals across the country and have been sold to more than 30 countries in Europe, Asia, Africa, and South America. Overseas intraocular lens revenue increased by 115 year-on-year75%。
In order to solve the myopia of teenagers, Aibo Medical launched the "Puno Pupil" orthokeratology lens, which has become the company's second product growth point.
This year, the company acquired Fujian Youyoukang Optics, entered the first-class glasses market, and created a third product growth point.
Future outlook
Aibo Medical has grown rapidly in the past few years, and there are still multiple product growth points in the future, and there is also a large market space in overseas markets.
Compared with its main competitors, Haohai Biotechnology and OPCOM, Aibo Medical attaches more importance to research and development and has leading technological advantages.
Note 1: Definition of China's ** champion enterprise: 1, not concerned by the public;2. Revenue exceeds years of continuous growth;3. It has a high market share in the market segment and is in a leading position in the industry.
Note 2: I do not hold the ** in this article, and this article does not constitute investment advice.